Patrick Burnett - 30 Dec 2021 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Role
Senior Vice President and Chief Medical Officer
Signature
/s/ Scott Burrows, as Attorney-in-Fact for Patrick Burnett
Issuer symbol
ARQT
Transactions as of
30 Dec 2021
Net transactions value
$0
Form type
4
Filing time
04 Jan 2022, 20:05:30 UTC
Next filing
07 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARQT Common Stock Award $0 +16,750 +176% $0.000000 26,250 30 Dec 2021 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On August 3, 2020, the Reporting Person was granted performance-based restricted stock units ("RSUs") subject to a milestone condition. The Compensation Committee of the Issuer certified the achievement of the milestone and commencement of vesting on December 30, 2021 (the "Milestone Vesting Commencement Date"). 25% of the performance-based RSUs shall vest annually from the Milestone Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.
F2 Includes 26,250 RSUs.

Remarks:

Senior Vice President and Chief Medical Officer